ATE368052T1 - Cd8 tuberkulose impfstoffe - Google Patents

Cd8 tuberkulose impfstoffe

Info

Publication number
ATE368052T1
ATE368052T1 AT01109298T AT01109298T ATE368052T1 AT E368052 T1 ATE368052 T1 AT E368052T1 AT 01109298 T AT01109298 T AT 01109298T AT 01109298 T AT01109298 T AT 01109298T AT E368052 T1 ATE368052 T1 AT E368052T1
Authority
AT
Austria
Prior art keywords
tuberculosis vaccines
vaccines
tuberculosis
epitopes
esat
Prior art date
Application number
AT01109298T
Other languages
German (de)
English (en)
Inventor
Ajit Lalvani
Roger Hamilton Brookes
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10803428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE368052(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE368052T1 publication Critical patent/ATE368052T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
AT01109298T 1996-11-25 1997-11-25 Cd8 tuberkulose impfstoffe ATE368052T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9624456.1A GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method

Publications (1)

Publication Number Publication Date
ATE368052T1 true ATE368052T1 (de) 2007-08-15

Family

ID=10803428

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01109298T ATE368052T1 (de) 1996-11-25 1997-11-25 Cd8 tuberkulose impfstoffe
AT97913336T ATE213068T1 (de) 1996-11-25 1997-11-25 Testverfahren für peptidspezifische t-zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97913336T ATE213068T1 (de) 1996-11-25 1997-11-25 Testverfahren für peptidspezifische t-zellen

Country Status (11)

Country Link
US (3) US7575870B1 (enExample)
EP (2) EP0941478B2 (enExample)
JP (1) JP4094674B2 (enExample)
AT (2) ATE368052T1 (enExample)
AU (1) AU728357C (enExample)
CA (1) CA2272881C (enExample)
DE (2) DE69710360T3 (enExample)
DK (2) DK0941478T4 (enExample)
ES (1) ES2172773T5 (enExample)
GB (1) GB9624456D0 (enExample)
WO (1) WO1998023960A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
CA2348475A1 (en) 1998-11-04 2000-05-11 Isis Innovation Limited Tuberculosis diagnostic test
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
GB0006692D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Epitopes
US20030198941A1 (en) * 2000-04-12 2003-10-23 Watkins David I. Method for making an HIV vaccine
WO2002054072A2 (en) 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
DE10125730A1 (de) * 2001-05-17 2002-11-21 A I D Autoimmun Diagnostika Gm Verfahren zum Nachweis von Erregern und durch diese induzierten zellulär produzierten Stoffen im lebenden Organismus
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US7153659B2 (en) * 2003-09-05 2006-12-26 Genencor International, Inc. HPV CD8+ T-cell epitopes
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
ES2648792T3 (es) 2004-04-28 2018-01-08 Btg International Limited Epítopos relacionados con la enfermedad celiaca
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP1781313A4 (en) 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
GB0619853D0 (en) 2006-10-06 2006-11-15 Oxford Immunotec Ltd Preparation method
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
JP2012503206A (ja) 2008-09-22 2012-02-02 オレゴン ヘルス アンド サイエンス ユニバーシティ Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染を検出するための方法
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
EP2501397B1 (en) 2009-11-20 2017-10-04 Oregon Health and Science University Methods for producing an immune response to tuberculosis
IT1403092B1 (it) 2010-12-01 2013-10-04 Univ Degli Studi Modena E Reggio Emilia Metodo per la diagnosi e/o il monitoraggio della mucormicosi.
WO2012103315A2 (en) 2011-01-27 2012-08-02 Osa Holdings, Inc. Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
FR2983213B1 (fr) 2011-11-30 2015-03-06 Commissariat Energie Atomique Procede de mesure en temps reel des secretions individuelles d'une cellule
WO2013093512A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccine - screening method
GB201122297D0 (en) 2011-12-23 2012-02-01 Retroscreen Virology Ltd Vaccine - screening method
US9678071B2 (en) 2012-01-12 2017-06-13 Mayo Foundation For Medical Education And Research Detecting latent tuberculosis infections
WO2013139972A1 (en) * 2012-03-23 2013-09-26 Laboratorios Del Dr. Esteve, S.A. Method for monitoring hiv specific t cell responses
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
EP3134730A4 (en) 2014-04-24 2018-01-17 Immusant Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
CA2962920C (en) 2014-10-01 2023-03-14 Cryosa, Llc Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
CA2968422A1 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
FR3033333A1 (fr) 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
CN110073215B (zh) 2016-09-22 2024-04-30 佩斯诊断公司 结核分枝杆菌蛋白诊断测定和结核病检测和诊断装置
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
WO2018111536A1 (en) 2016-12-14 2018-06-21 Becton, Dickinson And Company Methods and compositions for obtaining a tuberculosis assessment in a subject
WO2019018607A1 (en) 2017-07-20 2019-01-24 Enzo Biochem, Inc. IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF
KR102182555B1 (ko) * 2019-03-14 2020-11-24 한국과학기술연구원 T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
US20220214332A1 (en) 2019-05-30 2022-07-07 Oregon Health & Science University Methods for Detecting A Mycobacterium Tuberculosis Infection
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
CA3243280A1 (en) 2021-12-30 2023-07-06 Cryosa, Inc. SYSTEMS AND METHODS FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1299099C (en) 1986-03-06 1992-04-21 Paul Richard Wood In vitro assay for detecting cell-mediated immune responses
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
US20020136733A1 (en) 1994-03-31 2002-09-26 Hill Adrian Vivian Sinton Malaria peptides
WO1997000067A1 (en) * 1995-06-15 1997-01-03 University Of Victoria Innovation And Development Mycobacterium tuberculosis dna sequences encoding immunostimulatory peptides
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
CA2348475A1 (en) * 1998-11-04 2000-05-11 Isis Innovation Limited Tuberculosis diagnostic test
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
WO2002054072A2 (en) 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method

Also Published As

Publication number Publication date
CA2272881A1 (en) 1998-06-04
US20140087399A1 (en) 2014-03-27
US7575870B1 (en) 2009-08-18
DE69737956T2 (de) 2008-04-17
EP0941478A1 (en) 1999-09-15
DE69710360T2 (de) 2002-11-14
GB9624456D0 (en) 1997-01-15
DE69737956D1 (de) 2007-09-06
EP1152012A1 (en) 2001-11-07
ATE213068T1 (de) 2002-02-15
JP2001505568A (ja) 2001-04-24
DK1152012T3 (da) 2007-11-26
EP0941478B1 (en) 2002-02-06
AU728357C (en) 2001-11-01
WO1998023960A1 (en) 1998-06-04
EP1152012B1 (en) 2007-07-25
DE69710360D1 (de) 2002-03-21
AU728357B2 (en) 2001-01-04
US8617821B2 (en) 2013-12-31
CA2272881C (en) 2007-10-09
DE69710360T3 (de) 2008-01-17
ES2172773T3 (es) 2002-10-01
US9360480B2 (en) 2016-06-07
US20100203568A1 (en) 2010-08-12
ES2172773T5 (es) 2008-01-16
EP0941478B2 (en) 2007-06-06
AU5063298A (en) 1998-06-22
JP4094674B2 (ja) 2008-06-04
DK0941478T3 (da) 2002-07-01
DK0941478T4 (da) 2007-10-08

Similar Documents

Publication Publication Date Title
DE69737956D1 (de) CD8 Tuberkulose Impfstoffe
BR9406652A (pt) Composição
DE69334076D1 (de) Hla bindepeptide und ihre verwendungen
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
TR199701252T1 (xx) Bir saponin ve bir sterol i�eren a��lar.
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
ATE536187T1 (de) Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
DE69836588D1 (de) Tuberkulose impfstoff
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO20005050D0 (no) Fusjonsproteiner fra Mycobacterium Tuberculosis-antigener og deres anvendelse
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
GB9409985D0 (en) Vaccine against mycobacterial infections
DE58909762D1 (de) Bacillus thuringiensis Transformation
ATE429247T1 (de) Hla-bindende peptide und ihre verwendungen
DE69525058D1 (de) Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle
NO20005081D0 (no) Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
DK469188D0 (da) Fremgangsmaade og indretning til tilvejebringelse af personlig luftkonditionering
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
KR940023996U (ko) 이·미용용 중화제 분사기
KR940018852U (ko) 등산용 배낭의 에어 쿠션 장치
KR940024005U (ko) 이·미용용 중화제 보온기

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties